Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$76.01

3.38 (4.65%)

17:52
09/29/19
09/29
17:52
09/29/19
17:52

Seattle Genetics price target raised to $95 from $75 at Piper Jaffray

Piper Jaffray analyst Joseph Catanzaro raised his price target for Seattle Genetics to $95 from $75 after the company presented a "compelling" initial response rate of 71% for the combination of EV and pembrolizumab in 1st-line cisplatin-ineligible urothelial bladder cancer. While "admittedly early," these data compare very favorably to current standard of care and emerging IO combos, he contends. As such, the analyst believes it is reasonable to layer in this opportunity into his EV model, which he previously excluded. Catanzaro reiterates an Overweight rating on the shares and sees potential for further upside from additional UBC opportunities and possibly tucatinib in HER2+ mCRC.

SGEN Seattle Genetics
$76.01

3.38 (4.65%)

09/12/19
09/12/19
UPGRADE
Target $82

Outperform
Seattle Genetics upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
09/27/19
GSCO
09/27/19
UPGRADE
Target $100
GSCO
Buy
Seattle Genetics upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter upgraded Seattle Genetics to Buy from Neutral and raised his price target for the shares to $100 from $78. The stock closed Thursday down 99c to $72.63. With continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, the analyst expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. He expects approval of enfortumab vedotin by the March 15, 2020 action data and is positive on Seattle's two-late stage assets, tucatinib in HER2+ metastatic breast cancer and tisotumab vedotin in metastatic cervical cancer, with results by year-end 2019 and the first half of 2020, respectively.
09/27/19
09/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Western Union (WU) upgraded to Buy from Neutral at Guggenheim with analyst Jeff Cantwell citing what he called the company's "positive" investor day where management outlined "a solid 3-year growth trajectory." 2. Applied Genetic (AGTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Matthew Luchini saying the early XLRP data suggest potential for vision stabilization in peripherally treated patients and vision improvement in centrally treated patients. 3. Seattle Genetics (SGEN) upgraded to Buy from Neutral at Goldman Sachs with analyst Salveen Richter saying with continued Adcetris growth in Hodgkin's lymphoma and peripheral T cell lymphoma, he expects "multiple near-term pipeline drivers to cement" the company's transition into a multi-product oncology company. 4. Match Group (MTCH) upgraded to Outperform from In Line at Evercore ISI. 5. Texas Instruments (TXN) upgraded to Buy from Neutral at BofA/Merrill with analyst Vivek Arya saying he is positive on Texas Instruments' market share gains, stronger free cash flow returns, stronger positioning in growth areas such as 5G, Internet-of-Things, and Electric vehicles. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/19
PIPR
09/29/19
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray says some may be disappointed by Immunomedics TROPHY response rate
Piper Jaffray analyst Joseph Catanzaro notes that Immunomedics (IMMU) presented interim data from the Phase II TROPHY study of sacituzumab govitecan in postchemo/CPI urothelial bladder cancer at ESMO. Overall, the response rate of 29% is consistent with prior Phase I data, but he does believe some could be disappointed by this number as it relates to Seattle Genetics' (SGEN) 44% ORR for EV. Catanzaro would await more mature data before drawing any definitive conclusions on the competitive positioning of sacituzumab and EV in post-chemo/IO UBC, but ultimately believes the SC ORR in a larger cohort is approvable and that both drugs will play important roles in this landscape. He reirerates an Overweight rating and $20 price target on Immunomedics's shares.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$12.35

0.06 (0.49%)

, LOW

Lowe's

$112.40

1.735 (1.57%)

11:05
10/15/19
10/15
11:05
10/15/19
11:05
On The Fly
Bed Bath & Beyond, Lowe's upgrades among today's top analyst calls »

Check out today's top…

BBBY

Bed Bath & Beyond

$12.35

0.06 (0.49%)

LOW

Lowe's

$112.40

1.735 (1.57%)

BLMN

Bloomin' Brands

$17.61

-0.54 (-2.98%)

SFIX

Stitch Fix

$21.07

-0.14 (-0.66%)

NVDA

Nvidia

$194.87

8.36 (4.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 20

    Nov

  • 20

    Nov

GS

Goldman Sachs

$201.90

-3.91 (-1.90%)

11:05
10/15/19
10/15
11:05
10/15/19
11:05
Hot Stocks
Goldman Sachs sees global GDP growth in excess of 3% for this year and next »

Comments taken from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 12

    Nov

BHC

Bausch Health

$21.10

0.19 (0.91%)

11:04
10/15/19
10/15
11:04
10/15/19
11:04
Periodicals
Breaking Periodicals news story on Bausch Health »

Citron Research says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

ON

ON Semiconductor

$19.52

0.65 (3.44%)

11:03
10/15/19
10/15
11:03
10/15/19
11:03
Hot Stocks
ON Semiconductor, Almotive collaborate on prototype sensor fusion platforms »

ON Semiconductor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

MDP

Meredith

$35.26

0.56 (1.61%)

11:02
10/15/19
10/15
11:02
10/15/19
11:02
Hot Stocks
Meredith appoints Daphne Kwon Chief Strategy Officer »

Meredith Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

NURO

NeuroMetrix

$0.32

-0.0096 (-2.91%)

11:02
10/15/19
10/15
11:02
10/15/19
11:02
Hot Stocks
NeuroMetrix shifting to exclusively direct-to-consumer model for Quell 2.0 »

NeuroMetrix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

WSLFF

Westleaf

$0.00

(0.00%)

11:01
10/15/19
10/15
11:01
10/15/19
11:01
Hot Stocks
Westleaf announces receipt of Health Canada standarad processing license »

Westleaf announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$69.25

-1.58 (-2.23%)

10:55
10/15/19
10/15
10:55
10/15/19
10:55
Options
Zoom Video Communications put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Dec

BHKLY

BOC Hong Kong

$0.00

(0.00%)

10:53
10/15/19
10/15
10:53
10/15/19
10:53
Upgrade
BOC Hong Kong rating change  »

BOC Hong Kong upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGLD

Royal Gold

$118.16

-6.81 (-5.45%)

10:48
10/15/19
10/15
10:48
10/15/19
10:48
Hot Stocks
Royal Gold appoints Mark Isto as COO, Paul Libner as CFO »

Royal Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

10:45
10/15/19
10/15
10:45
10/15/19
10:45
General news
Breaking General news story  »

4-Week Bill Announcement…

10:45
10/15/19
10/15
10:45
10/15/19
10:45
General news
Breaking General news story  »

8-Week Bill Announcement…

TNDM

TNDM

, ABT

Abbott

$81.40

1.59 (1.99%)

10:44
10/15/19
10/15
10:44
10/15/19
10:44
On The Fly
Tandem Diabetes jumps after announcing partnership with Abbott »

Shares of Tandem Diabetes…

TNDM

TNDM

ABT

Abbott

$81.40

1.59 (1.99%)

DXCM

DexCom

$149.39

-10.81 (-6.75%)

PODD

Insulet

$154.18

1.88 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

RETA

Reata Pharmaceuticals

$155.99

55.62 (55.42%)

10:43
10/15/19
10/15
10:43
10/15/19
10:43
Recommendations
Reata Pharmaceuticals analyst commentary  »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMR

Emerson

$67.29

0.08 (0.12%)

10:42
10/15/19
10/15
10:42
10/15/19
10:42
Hot Stocks
Emerson says will 'carefully evaluate' D.E. Shaw's proposals »

Emerson confirmed receipt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BAC

Bank of America

$29.43

0.28 (0.96%)

10:38
10/15/19
10/15
10:38
10/15/19
10:38
Hot Stocks
Bank of America reports September charge-off rate 2.62% vs. 2.67% last month »

Reports September 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

GM

General Motors

$35.89

0.38 (1.07%)

10:36
10/15/19
10/15
10:36
10/15/19
10:36
Periodicals
General Motors, UAW closer to reaching agreement, says Phil LeBeau »

CNBC contributor Phil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SPY

SPDR S&P 500 ETF Trust

$298.16

2.15 (0.73%)

, SPX

S&P 500

$0.00

(0.00%)

10:35
10/15/19
10/15
10:35
10/15/19
10:35
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

EU negotiators closing in…

SPY

SPDR S&P 500 ETF Trust

$298.16

2.15 (0.73%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRAY

ViewRay

$2.69

0.115 (4.47%)

10:35
10/15/19
10/15
10:35
10/15/19
10:35
Recommendations
ViewRay analyst commentary  »

ViewRay preannounced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INSW

International Seaways

$25.60

-0.28 (-1.08%)

10:29
10/15/19
10/15
10:29
10/15/19
10:29
Conference/Events
International Seaways management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 22

    Oct

AXL

American Axle

$8.03

0.165 (2.10%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Options
American Axle call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$59.25

-0.77 (-1.28%)

10:25
10/15/19
10/15
10:25
10/15/19
10:25
Conference/Events
WNS Holdings management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 11

    Nov

C

Citi

$70.26

-0.02 (-0.03%)

10:23
10/15/19
10/15
10:23
10/15/19
10:23
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi says accrual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi now sees net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

C

Citi

$70.29

0.01 (0.01%)

10:22
10/15/19
10/15
10:22
10/15/19
10:22
Hot Stocks
Citi sees expenses down sequentially in Q4, 'solid' pre-tax earnings growth »

For Q4 in ICG, Citi sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.